首页|期刊导航|中华医学杂志（英文版）|Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase Ⅲ China-centric study, MEASURE 5

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase Ⅲ China-centric study, MEASURE 5

Feng Huang Yi Wang Hao-Min Qiu Brian Porter Sibylle Haemmerle Fei Sun Wei-Guo Wan Li-Jun Wu Ling-Li Dong Xiao Zhang Tae-Hwan Kim Raj Sengupta Ladislav Senolt

中华医学杂志（英文版）2020，Vol.133Issue(21)：2521-2531,11.

中华医学杂志（英文版）2020，Vol.133Issue(21)：2521-2531,11.DOI:10.1097/CM9.0000000000001099

Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase Ⅲ China-centric study, MEASURE 5

Feng Huang ¹Yi Wang ²Hao-Min Qiu ³Brian Porter ²Sibylle Haemmerle ⁴Fei Sun ¹Wei-Guo Wan ⁵Li-Jun Wu ⁶Ling-Li Dong ⁷Xiao Zhang ⁸Tae-Hwan Kim ⁹Raj Sengupta ¹⁰Ladislav Senolt¹¹

作者信息

1. Department of Rheumatology, Chinese People's Liberation Army General Hospital, Beijing 100853, China
2. Novartis Pharmaceuticals Corporation, East Hanover, N J, USA
3. China Novartis Institutes for Biomedical Research, Shanghai 201203, China
4. Novartis Pharma AG, Basel, Switzerland
5. Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China
6. Department of Rheumatology & Immunology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang 830001, China
7. Department of Rheumatology & Immunology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, Wuhan, Hubei 430030, China
8. Department of Rheumatology & Immunology, Guangdong General Hospital, Guangzhou, Guangdong 510000, China
9. Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
10. Royal National Hospital for Rheumatic Disease, Upper Borough Walls, Bath BA1 1RL, UK
11. Institute of Rheumatology, Prague, Czech Republic
折叠

摘要

关键词

Ankylosing spondylitis/Biologics/Cytokines/Interleukin 17A/Tumor necrosis factor

Key words

Ankylosing spondylitis/Biologics/Cytokines/Interleukin 17A/Tumor necrosis factor

引用本文复制引用

Feng Huang,Yi Wang,Hao-Min Qiu,Brian Porter,Sibylle Haemmerle,Fei Sun,Wei-Guo Wan,Li-Jun Wu,Ling-Li Dong,Xiao Zhang,Tae-Hwan Kim,Raj Sengupta,Ladislav Senolt..Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, Phase Ⅲ China-centric study, MEASURE 5[J].中华医学杂志（英文版）,2020,133(21):2521-2531,11.

基金项目

This study was supported by Novartis Pharma AG,Basel,Switzerland and designed by Novartis personnel.Medical writing support was funded by Novartis. （）

中华医学杂志（英文版）

OACSCDCSTPCDMEDLINESCI

ISSN：0366-6999

访问量0

下载量0

段落导航